Aarti Drugs Ltd.'s subsidiary Pinnacle Life Science Pvt. has received the Establishment Inspection Report from the US Food and Drug Administration for its manufacturing facility located in Baddi, Himachal Pradesh.
The US FDA conducted an inspection at the manufacturing facility on April 23, as per an exchange filing.
ADVERTISEMENT
The company's first-quarter net profit declined over 30% to Rs 33.24 crore in the June quarter, as compared to Rs 47.85 crore in the same period last year. The company's revenue stood at Rs 555.34 crore in June, down 16% from Rs 661.11 crore over the same period last year.
Shares of Aarti Drugs closed 4.41% lower at Rs 503.25 apiece, as compared to a 0.03% advance in the BSE Sensex.
WRITTEN BY
ADVERTISEMENT
RECOMMENDED FOR YOU

Novo Nordisk Launches Weight-Loss Drug Wegovy In India Starting From Rs 17,300


Cognizant To Invest Rs 1,582 Crore For New Visakhapatnam Campus, Gets Land For 99 Paise


Sun Pharma Share Price Fell Nearly 2% After US FDA Issues Eight Observations


Aarti Industries Shares Get Double Upgrade From UBS On Likely Cycle Recovery, Strategic Growth Initiatives
